NUCALA IMPROVED LOSS OF SMELL AND OVERALL NASAL POLYP SYMPTOMS

NUCALA significantly improved loss of smell1

SECONDARY ENDPOINT: LOSS OF SMELL*

Graph of LS mean change from baseline in two different baseline patient populations showing the reduced loss of smell (secondary endpoint) Graph of LS mean change from baseline in two different baseline patient populations showing the reduced loss of smell (secondary endpoint)

*Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).
†LS means from an analysis using mixed model repeated measures.

SYNAPSE study design

Loss of smell with fewer prior surgeries

GREATER IMPROVEMENTS IN LOSS OF SMELL SCORE WITH FEWER PRIOR SURGERIES

Table displaying the greater improvements in loss of smell score in patients with fewer prior surgeries in placebo-treated and NUCALA-treated patients Table displaying the greater improvements in loss of smell score in patients with fewer prior surgeries in placebo-treated and NUCALA-treated patientsResults are descriptive.

SYNAPSE study design

Request a rep

Want to know more?

Request a rep

Sense of smell improvement observed by second dose of NUCALA2

Graph of LS mean improvement from baseline in loss of smell VAS against time period comparing NUCALA and placebo results showing the sense of smell improvement observed by second dose of NUCALA Graph of LS mean improvement from baseline in loss of smell VAS against time period comparing NUCALA and placebo results showing the sense of smell improvement observed by second dose of NUCALAResults prior to Weeks 49-52 are descriptive.

NUCALA + SOC (n=206; baseline score, 9.63)

Placebo + SOC (n=201; baseline score, 9.68)

LS mean† change from baseline in loss of smell VAS score* at Weeks 5-8: NUCALA –0.85 vs placebo –0.38. Treatment difference: –0.46 (95% CI: –0.75, –0.17). Results are descriptive.

Secondary endpoint: LS mean† change from baseline in loss of smell VAS score* at Weeks 49-52: NUCALA –2.92 vs placebo –1.46; P<0.001.

*Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).
†LS means from an analysis using mixed model repeated measures.

SYNAPSE study design

Improved overall nasal polyp symptoms1,2

Graph of LS mean change from baseline comparing the impact of NUCALA and placebo on nasal polyp symptoms that shows an improvement to all symptoms Graph of LS mean change from baseline comparing the impact of NUCALA and placebo on nasal polyp symptoms that shows an improvement to all symptoms

*Symptom severity measured on patient-reported VAS from 0 (none) to 10 (as bad as you can imagine).

†LS means from an analysis using mixed model repeated measures.

‡Patient evaluation of overall nasal polyp symptoms recorded daily.

SYNAPSE study design

CI=confidence interval; LS=least squares; SOC=standard of care; VAS=visual analog scale.

Reduced nasal polyp surgery icon

Learn how NUCALA reduced nasal polyp surgery

SEE SURGERY DATA

NUCALA Prescription

Navigate a NUCALA prescription

Get patients started